Skip to main content
logo
Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.470
-0.030 (-2.00%)
May 5, 2026, 11:56 AM EDT - Market open

Akebia Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
236.2160.18194.62292.48211.65
Revenue Growth (YoY)
47.46%-17.70%-33.46%38.19%-28.17%
Cost of Revenue
39.4663.1874.1585.57150.67
Gross Profit
196.7397120.47206.9260.98
Selling, General & Admin
107.48106.55100.23138.6174.14
Research & Development
62.3637.6563.08129.99147.85
Other Operating Expenses
3.43.283.4219.113.49
Total Operating Expenses
173.24147.48166.73287.7325.48
Operating Income
23.5-50.47-46.26-80.78-264.5
Interest Expense
-24.18-18.19-6.03-15.69-
Other Non-Operating Income (Expense)
-3.04-0.750.362.24-17.52
Total Non-Operating Income (Expense)
-27.22-18.94-5.67-13.45-17.52
Pretax Income
-3.72-69.41-51.93-94.23-282.02
Provision for Income Taxes
1.62----
Net Income
-5.35-69.41-51.93-94.23-282.02
Net Income to Common
-5.35-69.41-51.93-94.23-282.02
Shares Outstanding (Basic)
257211187183166
Shares Outstanding (Diluted)
257211187183166
Shares Change (YoY)
21.91%12.53%2.56%10.14%19.85%
EPS (Basic)
-0.02-0.33-0.28-0.52-1.70
EPS (Diluted)
-0.02-0.33-0.28-0.52-1.70
Shares Outstanding
265.43224.85194.58184.14177
Free Cash Flow
67.7-40.69-23.38-73.27-253.02
Free Cash Flow Per Share
0.26-0.19-0.12-0.40-1.52
Gross Margin
83.29%60.56%61.90%70.74%28.81%
Operating Margin
9.95%-31.51%-23.77%-27.62%-124.97%
Profit Margin
-2.26%-43.33%-26.68%-32.22%-133.25%
FCF Margin
28.66%-25.40%-12.02%-25.05%-119.55%
EBITDA
24.77-12.97-8.63-43.08-226.53
EBITDA Margin
10.49%-8.10%-4.43%-14.73%-107.03%
EBIT
23.5-50.47-46.26-80.78-264.5
EBIT Margin
9.95%-31.51%-23.77%-27.62%-124.97%
Effective Tax Rate
-43.64%0.00%0.00%0.00%0.00%
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q